ALTA-3263

About Alterome Therapeutics

Alterome Therapeutics is a private, pre-revenue biotech advancing a novel precision oncology pipeline targeting historically undruggable drivers like KRAS and AKT E17K mutations. Leveraging a team with deep expertise in computational drug design and oncology development, the company has rapidly progressed two internally discovered, first-of-their-kind molecules into clinical trials within four years of its founding. With a strong leadership team and backing from top-tier life science investors, Alterome aims to redefine cancer treatment by targeting specific genetic alterations to improve patient outcomes in high-need oncology indications.

Therapeutic Areas

Other KRAS-driven cancers Drugs